Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab combined with apatinib or mXELOX for stage IIb/IIIa hepatocellular carcinoma
ChiCTR2000035279Phase 2Recruiting
- Sponsor
- Harbin Medical University Cancer Hospital
- Start
- Aug 2020
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of camrelizumab, Rivoceranib, oxaliplatin and capecitabine in hepatocellular carcinoma (HCC) (2 arms), sponsored by Harbin Medical University Cancer Hospital. Primary endpoint: Surgical conversion success rate. Started Aug 2020; status: recruiting.
02
Drugs
camrelizumabRivoceraniboxaliplatincapecitabine
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR2000035279.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000035279.